GMAB.DK

1,639.5

-2.96%↓

COLO.B.DK

402.3

+0.07%↑

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

GMAB.DK

1,639.5

-2.96%↓

COLO.B.DK

402.3

+0.07%↑

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

GMAB.DK

1,639.5

-2.96%↓

COLO.B.DK

402.3

+0.07%↑

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

GMAB.DK

1,639.5

-2.96%↓

COLO.B.DK

402.3

+0.07%↑

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

GMAB.DK

1,639.5

-2.96%↓

COLO.B.DK

402.3

+0.07%↑

HLUNB.DK

43.04

+1.46%↑

ZEAL.DK

344.6

+11.45%↑

AMBUB.DK

62.6

-3.99%↓

Начало・Списък с акции・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Затворен

290.64 4.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

288

Максимум

291.39

Ключови измерители
By Trading Economics
Приходи	6.9B 27B
Продажби	4.2B 79B
P/E Средно за сектора	12.076 49.8
EPS	6.04
Дивидентна доходност	4.21
Марж на печалбата	33.977
Служители	68,794
EBITDA	3.5B 37B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+9.53% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	4.21% 2.25%
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-404B 1.3T
Предишно отваряне	285.96
Предишно затваряне	290.64

Novo Nordisk A-S (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.05.2026 г., 07:30 ч. UTC

Печалби

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6.05.2026 г., 06:19 ч. UTC

Печалби

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

7.05.2026 г., 09:30 ч. UTC

Печалби

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6.05.2026 г., 12:36 ч. UTC

Печалби

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6.05.2026 г., 10:53 ч. UTC

Горещи акции

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6.05.2026 г., 10:12 ч. UTC

Печалби

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6.05.2026 г., 09:58 ч. UTC

Печалби

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6.05.2026 г., 09:35 ч. UTC

Горещи акции

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6.05.2026 г., 08:13 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6.05.2026 г., 07:43 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6.05.2026 г., 07:00 ч. UTC

Печалби

Novo Nordisk Shares Rise 5.5% After 1Q Results

6.05.2026 г., 06:34 ч. UTC

Печалби

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6.05.2026 г., 06:26 ч. UTC

Печалби

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6.05.2026 г., 06:26 ч. UTC

Печалби

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6.05.2026 г., 06:24 ч. UTC

Печалби

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6.05.2026 г., 06:20 ч. UTC

Печалби

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6.05.2026 г., 06:19 ч. UTC

Печалби

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6.05.2026 г., 06:13 ч. UTC

Печалби

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6.05.2026 г., 06:13 ч. UTC

Печалби

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6.05.2026 г., 06:12 ч. UTC

Печалби

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6.05.2026 г., 05:43 ч. UTC

Печалби

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6.05.2026 г., 05:42 ч. UTC

Печалби

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6.05.2026 г., 05:40 ч. UTC

Печалби

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

6.05.2026 г., 05:40 ч. UTC

Печалби

Novo Nordisk 1Q Op Margin 61.6%

6.05.2026 г., 05:39 ч. UTC

Печалби

Novo Nordisk 1Q Gross Margin 85.9%

6.05.2026 г., 05:39 ч. UTC

Печалби

Novo Nordisk 1Q Wegovy Injectable Sales Rose 12% at CER To DKK 18.24B, Consensus Saw DKK16.85B

6.05.2026 г., 05:38 ч. UTC

Печалби

Novo Nordisk 1Q Ozempic Drug Sales Fell 8% at CER To DKK27.83B, Consensus Saw DKK26.4B

6.05.2026 г., 05:36 ч. UTC

Печалби

Novo Nordisk: Analysts Saw 1Q Net Profit At DKK23.3B

6.05.2026 г., 05:36 ч. UTC

Печалби

Novo Nordisk 1Q Net Pft DKK48.56B

6.05.2026 г., 05:36 ч. UTC

Печалби

Novo Nordisk: Analysts Saw 1Q Op Pft at DKK49.11B

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S (Class B) Прогноза

Ценова цел

By TipRanks

9.53% нагоре

12-месечна прогноза

Среден 1,162.73 DKK 9.53%

Висок 1,550 DKK

Нисък 720 DKK

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S (Class B) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Novo Nordisk A-S (Class B) през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.